Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jaypirca is a prescription noncovalent Bruton tyrosine kinase inhibitor containing pirtobrutinib. It is indicated for selected adults with relapsed or refractory mantle cell lymphoma and for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after prior covalent BTK inhibitor treatment.
read more about jaypirca ...Pirtobrutinib is a small-molecule noncovalent inhibitor of Bruton tyrosine kinase. It binds wild-type BTK and BTK with C481 mutations, reducing kinase signaling involved in B-cell proliferation, trafficking, chemotaxis, and adhesion.
Jaypirca is used in adults with relapsed or refractory mantle cell lymphoma after at least two systemic treatment lines including a BTK inhibitor. It is also used in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor.
The recommended dose is 200 mg by mouth once daily until disease progression or unacceptable toxicity. Tablets are swallowed whole with water and can be taken with or without food. Severe kidney impairment, selected adverse reactions, and interacting CYP3A medicines can require dose changes or treatment interruption.
Serious concerns include severe infections, major bleeding, low blood-cell counts, atrial fibrillation and other cardiac arrhythmias, second primary cancers, liver toxicity including drug-induced liver injury, and fetal harm. Complete blood counts and liver tests are monitored during treatment.
Current labeling includes selected relapsed or refractory mantle cell lymphoma and relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in adults.
The recommended dose is 200 mg once daily.
No. Tablets are swallowed whole with water and are not cut, crushed, or chewed.
Yes. Major and fatal hemorrhage have occurred during treatment.
FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic. Date Accessed October 6, 2026.
FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pirtobrutinib-relapsed-or-refractory-mantle-cell-lymphoma. Date Accessed October 6, 2026.
FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic. Date Accessed October 6, 2026.
JAYPIRCA (Pirtobrutinib) Prescribing Information. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801. Date Accessed October 6, 2026.
Pirtobrutinib: MedlinePlus Drug Information. https://www.medlineplus.gov/druginfo/meds/a623012.html. Date Accessed October 6, 2026.